Company

BiOptix exists to make world-class label-free detection technologies more accessible to researchers worldwide.

BiOptix was originally established in 2008 as BiOptix Diagnostics in Boulder, Colorado, where we still are today. The company set out to develop its proprietary E-SPR (Enhanced Surface Plasmon Resonance) technology platform for the detection of molecular interactions. This technology was developed by BiOptix in conjunction with Dr. John ‘Jan’ Hall, Professor Adjunct of Physics at the University of Colorado, who was awarded the Nobel Prize for Physics in 2005.

John L. Hall receiving his Nobel Prize from His Majesty the King Carl XVI Gustaf of Sweden at the Stockholm Concert Hall, 10 December 2005. Copyright © The Nobel Foundation 2005 Photo: Hans Mehlin

The BiOptix line of Enhanced Surface Plasmon Resonance instruments has been designed to increase the flexibility and reliability of SPR, in order to address the increasing demand for instruments suitable for a broader range of applications, while offering a far greater performance per dollar than any other instruments available.

In 2010, BiOptix introduced the economical 104sa, which was the first commercial instrument to employ phase-based SPR technology. The 104sa had a single flow cell design with a quad array of sensors and included a powerful and user-friendly software package for instrument control and data analysis. In early 2013, BiOptix launched the 404pi which introduced increased automation capabilities while also utilizing the powerful E-SPR technology. This new class of instrumentation brings increased sensitivity, flexibility and the ability to measure protein-small molecule interactions (100 Da) in a higher throughput 96 well platform that utilizes 4 parallel channels rather than a single flow cell. The BiOptix 404pi is an affordable and powerful solution for scientists that require rapid, label-free, real-time detection of biomolecular interactions with a reasonable cost to own and operate.

BiOptix: Kinetics with Confidence.